Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30872476 | 0.84 | POLB (0.48) | LMNAMEN1KMT2ANPSR1TP53 | |
| SCHEMBL38653361 | 0.83 | LMNA (0.48) | LMNAMEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL38653670 | 0.82 | MEN1 (0.48) | LMNAMEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL38653877 | 0.82 | SMN1; SMN2 (0.48) | LMNAMEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL30867732 | 0.81 | TP53 (0.48) | LMNAMEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL38654243 | 0.79 | LMNA (0.47) | LMNAMEN1KMT2ANPSR1TP53 | |
| SCHEMBL38654432 | 0.79 | TP53 (0.52) | LMNAMEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL38653818 | 0.78 | LMNA (0.46) | LMNAMEN1KMT2ATP53MAPT | |
| SCHEMBL38653971 | 0.77 | LMNA (0.50) | LMNAMEN1KMT2ANPSR1TP53 | |
| SCHEMBL38654426 | 0.76 | LMNA (0.51) | LMNAMEN1KMT2ANPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | LMNA 1584/4885MEN1 830/4885KMT2A 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.